Introduction
============

Vascular inflammation is a key feature of vascular diseases, like hypertension or atherosclerosis, which are major causes of mortality worldwide ([@B7]). In the context of vascular diseases, vasoactive peptides, cytokines, and other agents, play a pivotal role in promoting vascular inflammation not only through the early recruitment of circulating leukocytes, but also during the progression of the disease through the activation of vascular smooth muscle cells (VSMC) ([@B16]; [@B6]). Indeed, activated VSMC can switch to a pro-inflammatory phenotype that drives the expression of a wide array of pro-inflammatory molecules and mediators, which in turn perpetuate and amplify the deleterious vascular environment ([@B16]; [@B6]). In this context, attenuating inflammation, by pharmacological tools or other approaches, is nowadays considered as a challenging strategy to prevent or delay the development of vascular diseases ([@B9]; [@B7]).

The renin-angiotensin system (RAS) is a key player in the regulation of cardiovascular homeostasis both in health and disease. Angiotensin (Ang)-II has been extensively studied over the last decades in the context of vascular pathophysiology, where it has proven to play a pivotal role in disrupting vascular homeostasis and promoting endothelial dysfunction and vascular remodeling through the activation of AT1 receptors ([@B3]). Ang II has also been extensively linked to vascular cell inflammation, through signaling pathways involving the generation of reactive oxygen species (ROS) and the activation of the transcription factor nuclear factor (NF)-κB, among other ([@B21]).

While Ang II has been for long acknowledged as the main biologically active peptide of the RAS, other components of the RAS have recently gained growing attention. Ang-(1-7) is a heptapeptide, mainly generated from Ang II through the action of angiotensin converting enzyme 2 (ACE2) but also from Ang I via neutral endopeptidase (NEP) activity ([@B27]). Ang-(1-7) is a ligand for the G protein-coupled receptor Mas ([@B15]). In the vasculature, Ang-(1-7) has been considered as a physiological antagonist of Ang II, since it displays vasodilatory, antiangiogenic, antiproliferative, antimigratory, antiapoptotic, and antihypertrophic properties, among other ([@B12]; [@B27]). Several of these vasculoprotective actions are mainly the result of the modulation of VSMC function by Ang-(1-7) ([@B43]; [@B1]; [@B4]). Little is known, however, on the direct anti-inflammatory properties of the heptapeptide on this vascular cell type.

In the present study, we evaluated the capacity of Ang-(1-7) to counteract the pro-inflammatory response triggered by Ang II in primary human VSMC cultures in terms of NF-κB activation and inducible nitric oxide synthase (iNOS) induction. Moreover, we tested the capacity of Ang-(1-7) to dampen inflammation beyond the RAS, by using the cytokine interleukin (IL)-1β to activate human VSMC. Finally, we studied the contribution of Mas receptors subtypes to the actions of Ang-(1-7) and partly dissected the pro-inflammatory intracellular pathways modulated by Ang-(1-7) in human VSMC.

Materials and Methods {#s1}
=====================

Materials
---------

Culture plastic ware was from TPP (Trasadingen, Switzerland). Dulbecco's Modified Eagle's Medium (DMEM), fetal calf serum (FCS), and trypsin-EDTA were from Biological industries (Beit-Hamek, Israel). IL-1β was from Peprotech (London, UK), while the Mas antagonists A779 and D-Pro^7^-Ang-(1-7) were purchased Bachem (Bubendorf, Switzerland) and Biosyntan (Berlin, Germany), respectively. Anakinra was purchased from Swedish Orphan Biovitrum AB (Stockholm, Sweden). Ang-(1-7), Ang II, losartan, apocynin, and pyrrolidine dithiocarbamate (PDTC) were purchased from Sigma (St. Louis, MO, USA).

Cell Culture
------------

Primary cultures of human aortic smooth muscle cells (HASMC) were obtained by enzymatic dissociation from aortic fragments of five organ donors free of vascular disease (two men and three women, age 35 ± 5.6 years), conforming to the principles outlined in the Declaration of Helsinki and according to Spanish legal regulations, as previously described ([@B30]). The study was approved by the Ethics Committee of Hospital Universitario de Getafe (CEIC 14/17). HASMC from the different donors were pooled and routinely cultured in DMEM supplemented with 10% FCS and antibiotics ([@B30]). For experiments, HASMC were deprived of serum for 24 h prior to the addition of different test compounds in serum-free medium supplemented with 0.1% BSA. Cultures between the third and the tenth passages were used.

Western Blot
------------

The levels of iNOS were determined by Western blot using a polyclonal antibody (Transduction Laboratories, Lexington, KY, USA; dilution 1/1,000), followed by an appropriate secondary peroxidase-conjugated antibody (Chemicon, Temecula, CA, USA; dilution 1/10,000), as previously described ([@B30]). Inmunoreactive bands were visualized by enhanced chemiluminescence detection (Millipore, Billerica, MA, USA), and quantified using ImageJ free software. For every experiment, iNOS levels were normalized to α-tubulin using a primary polyclonal antibody from Sigma (dilution 1/10,000).

Determination of Nitric Oxide Release
-------------------------------------

Nitric oxide (NO) was indirectly quantified in HASMC supernatants using the Griess Method, as previously described ([@B17]). For results normalization, protein content was determined by the Bradford assay.

Nuclear Extracts and Electromobility Shift Assay
------------------------------------------------

Nuclear extracts were obtained as described before ([@B30]). For electromobility shift assay (EMSA), a commercial oligonucleotide (Promega, Madison, WI, USA) encoding the NF-κB consensus sequence (5′-AGTTGAGGGGACTTTCCCAGGC-3′) was 5′-end labeled using \[γ-^32^P\]ATP and T4 polynucleotide kinase (Promega, Madison, WI, USA). For binding reactions, nuclear extracts (5 μg) were incubated on ice for 15 min in a reaction buffer \[40 mM HEPES (pH 7.0), 140 mmol/L NaCl, 5 mM dithiothreitol, 10 μg/mL BSA, 0.01% Nonidet P-40, 4% Ficoll, and 0.05 μg/mL poly(dI-dC).poly(dI-dC)\]. After addition of the labeled oligonucleotide (∼50,000 cpm) the reaction mix was further incubated for 20 min at room temperature. For competition experiments a 100-fold excess of unlabeled doubled-stranded oligonucleotide was added to the binding reaction. DNA-protein complexes were resolved on 4% non-denaturing polyacrylamide gels in 0.5x TBE (45 mmol/L Tris-borate, 1 mM EDTA, pH 8.0) at 4°C. Gels were dried and exposed to autoradiography at -80°C. The intensity of the resulting bands was quantified by densitometry, as previously described ([@B30]), using Image J free software. The DNA binding activity of NF-κB was abolished by PDTC (100 μM).

NADPH Oxidase Activity Assay
----------------------------

NADPH oxidase was measured by lucigenin-derived chemiluminescence, as described previously ([@B38]). Briefly, HASMC were washed in ice-cold phosphate-buffered saline, scraped and centrifuged. The resulting cell pellet was homogenized in lysis buffer (pH 7.0) containing 50 mM KH~2~PO~4~, 1 mM EGTA, and 150 mM sucrose. For every sample, the protein content was determined by the bicinchoninic acid method. Cell extracts (5 μg protein) were incubated in phosphate-buffered saline containing 5 μM lucigenin and 100 μM NADPH and luminiscence was then measured every 10 s for 5 min in a tube luminometer (Optocomp, MGM Instruments, Hamden, CT, USA). The enzymatic activity, which was sensitive to the blockade by apocynin (30 μM), was expressed as relative light units (RLUs)/μg of protein/min.

Statistical Analysis
--------------------

Results are expressed as mean ± SEM. Statistical analysis was performed using one-way ANOVA followed by Bonferroni *post hoc* test. *n* denotes the number of independent experiments. A *p-*value ≤0.05 was considered statistically significant.

Results
=======

Ang-(1-7) Inhibits the Induction of iNOS by Ang II and IL-1β
------------------------------------------------------------

The induction of iNOS, and the subsequent generation of NO is a major feature of the response of VSMC activated by pro-inflammatory stimuli ([@B6]). **Figure [1A](#F1){ref-type="fig"}** shows that exposing HASMC to Ang II (100 nM) for 18 h resulted in a marked enhancement of iNOS levels, as compared with untreated cultures. This effect was abolished by the AT1 antagonist losartan (1 μM), which had no effect on iNOS levels by itself (**Figure [1A](#F1){ref-type="fig"}**). The induction of iNOS by Ang II was inhibited by Ang-(1-7) (1 nM--1 μM) in a concentration-dependent manner (**Figure [1B](#F1){ref-type="fig"}**).

![**Ang-(1-7) inhibits inducible nitric oxide synthase (iNOS) induction elicited by Ang II or IL-1β in human aortic smooth muscle cells (HASMC). (A)** HASMC were stimulated with Ang II (100 nM) alone or in the presence of the AT1 receptor antagonist losartan (1 μM) for 18 h, after which iNOS levels were determined by Western blot and normalized to α-tubulin. **(B)** In another set of experiments, the impact of increasing concentrations of Ang-(1-7) (1 nM--1 μM) on iNOS induction by Ang II was tested. **(C)** The pro-inflammatory cytokine IL-1β (2.5 ng/mL) promoted iNOS induction, which was prevented by the IL1 receptor blocker anakinra (1 μg/mL). **(D)** As for Ang II, Ang-(1-7) prevented the induction of iNOS by IL-1β in a concentration-dependent manner. Results are expressed as mean ± SEM; *n* = 5. Representative blots are shown in the corresponding panels. ^∗^*p* \< 0.05 vs. untreated cultures, ^\#^*p* \< 0.05 vs. Ang II- or IL-1β-treated cultures, respectively.](fphar-07-00482-g001){#F1}

While Ang-(1-7) has been gradually acknowledged as a physiological antagonist of Ang II, very little is known about the capacity of Ang-(1-7) to modulate the pro-inflammatory responses elicited by RAS-independent agonists. **Figure [1C](#F1){ref-type="fig"}** shows that the pro-inflammatory cytokine IL-1β (2.5 ng/mL) promoted the induction of iNOS in HASMC, which was blocked in the presence of the IL1 receptor antagonist anakinra (1 μg/mL). As for Ang II, Ang-(1-7) was capable to attenuate the induction of iNOS elicited by IL-1β (**Figure [1D](#F1){ref-type="fig"}**). For subsequent experiments, Ang-(1-7) was used at a fixed concentration of 100 nM.

The Mas Antagonists A779 and D-Pro-Ang-(1-7) Prevent the Attenuation of iNOS Induction by Ang-(1-7)
---------------------------------------------------------------------------------------------------

Ang-(1-7) has been described as a ligand for the G-protein-coupled receptor Mas ([@B15]). In HASMC, the Mas receptor antagonist D-Ala^7^-Ang-(1-7) (A779; 1 μM) prevented the capacity of Ang-(1-7) to attenuate the induction of iNOS elicited by both Ang II and IL-1β, as shown by Western blot (**Figures [2A,B](#F2){ref-type="fig"}**) and by indirect immunofluorescence (**Figure [2C](#F2){ref-type="fig"}**). Accordingly, A779 also blocked the reduction of NO release elicited by Ang-(1-7) in cells stimulated with Ang II or IL-1β (**Figures [2D,E](#F2){ref-type="fig"}**). In the absence of Ang II or IL-1β, neither Ang-(1-7) nor A779 did modify by themselves iNOS levels (**Figure [2B](#F2){ref-type="fig"}**) or NO release (3.12 ± 0.93 and 2.98 ± 1.06 nmol/mg protein, respectively; *n* = 3--5).

![**The inhibition of iNOS induction mediated by Ang-(1-7) is dependent on Mas receptors.** After exposing HASMC for 18 h to **(A)** Ang II (100 nM) or **(B)** IL-1β (2.5 ng/mL) with or without 100 nM Ang-(1-7), iNOS levels were determined by Western blot. In some experiments, cells were pre-incubated with the Mas receptor antagonist A779 (1 μM). **(C)** iNOS levels (red) were also determined by indirect immunofluorescence in response to the different stimuli. Nuclei were counterstained with DAPI (blue) (400×). In another set of experiments, nitric oxide (NO) production was determined in the supernatants of HASMC exposed for 18 h to Ang II **(D)** or IL-1β **(E)**, with or without Ang-(1-7) and A779. The Mas receptor antagonist D-Pro^7^-Ang-(1-7) (1 μM) was also capable to block the inhibitory effect of Ang-(1-7) on iNOS induction by Ang II **(F)** or IL-1β **(G)**. Results are expressed as mean ± SEM; *n* = 5. Representative blots are shown in the corresponding panels. ^∗^*p* \< 0.05 vs untreated cultures, ^\#^*p* \< 0.05 vs Ang II- or IL-1β-treated cultures, respectively.](fphar-07-00482-g002){#F2}

The existence of several Mas receptor subtypes in the vasculature has been previously suggested based on the differential capacity of two Mas receptors blockers A779 and D-Pro^7^-Ang-(1-7) to fully counteract some biological actions of Ang-(1-7), such as vasodilation ([@B34]). In HASMC cultures, however, D-Pro^7^-Ang-(1-7) also blocked the inhibitory effects of Ang-(1-7) on iNOS induction (**Figures [2F,G](#F2){ref-type="fig"}**). D-Pro^7^-Ang-(1-7) alone did not modify iNOS levels (**Figure [2G](#F2){ref-type="fig"}**).

Ang-(1-7) Prevents NF-κB Activation
-----------------------------------

To gain insight into the signaling pathways influenced by Ang-(1-7), we next focused on NF-κB, as a pivotal transcription factor regulating the expression of inflammation-related proteins, including iNOS ([@B5]). Both Ang II and IL-1β promoted the activation of NF-κB (**Figures [3A,B](#F3){ref-type="fig"}**). This step that was necessary for the downstream induction of iNOS, since the NF-κB inhibitor PDTC abolished iNOS induction (**Figures [3C,D](#F3){ref-type="fig"}**). Ang-(1-7) was capable to attenuate NF-κB activation, and this effect was blocked by A779 (**Figures [3A,B](#F3){ref-type="fig"}**).

![**Ang-(1-7) reduces NF-κB activation via Mas receptors in HASMC.** The activation of NF-κB induced after 18 h incubation with **(A)** Ang II (100 nM) or **(B)** IL-1β (2.5 ng/mL) was blunted by the antioxidant NADPH oxidase inhibitor apocynin (30 μM) and significantly reduced by Ang-(1-7) (100 nM), as determined by EMSA. The effect of Ang-(1-7) was prevented by the Mas receptor antagonist A779 (1 μM). The induction of iNOS by Ang II **(C)** or IL-1β **(D)** was abolished by the NF-κB inhibitor pyrrolidine dithiocarbamate (PDTC) (100 μM). Representative blot or EMSA images are shown in the corresponding panels. Results are expressed as mean ± SEM; *n* = 4. ^∗^*p* \< 0.05 vs untreated cultures, ^\#^*p* \< 0.05 vs Ang II- or IL-1β-treated cultures, respectively.](fphar-07-00482-g003){#F3}

Ang-(1-7) Inhibits the Stimulation of NADPH Oxidase Activity
------------------------------------------------------------

NF-κB is a redox-sensitive factor that can be regulated by different sources of ROS. Among these, NADPH oxidase is a major ROS-generating enzyme in vascular cells and its over-activation has been linked to vascular damage ([@B25]). **Figures [4A,B](#F4){ref-type="fig"}** show that Ang-(1-7) was able to attenuate the stimulation of NADPH oxidase activity triggered by both Ang II and IL-1β in HASMC. The use of the antioxidant NADPH oxidase inhibitor apocynin revealed that NADPH oxidase activity was necessary for the consecutive downstream NF-κB activation (**Figures [3A,B](#F3){ref-type="fig"}**) and iNOS induction (**Figures [4C,D](#F4){ref-type="fig"}**) elicited by Ang II and IL-1β.

![**Ang-(1-7) reduces NADPH oxidase activity via Mas receptors.** In HASMC, Ang-(1-7) (100 nM) reduced the stimulation of NADPH oxidase observed after 18 h incubation with **(A)** Ang II (100 nM) or **(B)** IL-1β (2.5 ng/mL), and this effect was blocked by the Mas receptor antagonist A779 (1 μM). The inhibition of NADPH oxidase by the antioxidant inhibitor apocynin (30 μM) prevented the induction of iNOS by Ang II **(C)** or IL-1β **(D)**. Representative blots are shown in the corresponding panels. The NADPH oxidase activity is given as relative light units (RLUs)/μg protein/min. Results are expressed as mean ± SEM; *n* = 4. ^∗^*p* \< 0.05 vs untreated cultures, ^\#^*p* \< 0.05 vs Ang II- or IL-1β-treated cultures, respectively.](fphar-07-00482-g004){#F4}

Discussion
==========

Since inflammation is at the basis of a wide array of cardiovascular diseases, the identification of pharmacological tools to prevent or attenuate vascular cell inflammation has gained growing attention over the last years ([@B24]). In this study, we have identified Ang-(1-7) as a novel player in preventing the pro-inflammatory activation of human VSMC. More specifically, Ang-(1-7) attenuated the induction of iNOS, a NO-generating enzyme that is found over-activated in a series of vascular diseases running with low grade inflammation, such as atherosclerosis, hypertension or diabetic vasculopathy ([@B33]; [@B8]; [@B26]).

Over a decade ago, Mas was identified as the main receptor mediating the biological actions of Ang-(1-7) ([@B32]). The *Mas* proto-oncogene encodes a 7 transmembrane protein exhibiting features of G-protein coupled receptors ([@B32]). In the vasculature, the presence of more than one subtype of Mas receptors was proposed by [@B34] based on the capacity of D-Pro^7^-Ang-(1-7), but not of A779, to inhibit Ang-(1-7)-mediated vasodilation in rat aortas ([@B34]). More recently, an acute lung injury model has also pointed out the existence of more than one type of Mas receptors in the respiratory system ([@B14]). In contrast, we observed that D-Pro^7^-Ang-(1-7) and A779 were equivalent in blocking the effects of Ang-(1-7). This rather indicates that both antagonists target the same receptor in human VSMC and that a unique Mas subtype receptor thus mediates the anti-inflammatory effects of Ang-(1-7) in this cell type. Indeed, our findings are in line with other reports identifying a single Mas receptor, sensitive to both D-Pro^7^-Ang-(1-7) and A779 antagonism, mediating the vasorelaxant action of Ang-(1-7) in murine conductance and resistance arteries ([@B18]; [@B28]) as well as other non-vascular actions of the heptapeptide ([@B44]).

Through its binding to Mas receptors, Ang-(1-7) attenuated the Ang II-stimulated induction of iNOS in human VSMC. Indeed, the ACE2/Ang-(1-7) axis is nowadays regarded as an endogenous counterpart for ACE/Ang II axis, and is thus considered to play a key role in regulating and limiting the actions of a central player in cardiovascular physiopathology such as Ang II. In the cardiovascular system, Ang-(1-7) has proven to counterbalance the vasoconstrictor, pro-oxidant, pro-fibrotic, and hypertrophic actions of Ang II ([@B11]; [@B19]). We now demonstrate that Ang-(1-7) may also protect against VSMC inflammation elicited by the main biologically active peptide of the RAS.

However, one of the major findings of the present study is that the Ang-(1-7)/Mas axis not only counteracts the action of Ang II, but is also acts as an anti-inflammatory compound beyond the RAS. Pro-inflammatory cytokines, including IL-1β, are key contributors to the low-grade inflammatory environment that characterizes a wide array of vascular diseases ([@B29]). Indeed, high sensitivity C-reactive protein, used as a biomarker of cardiovascular risk, is now being considered as a downstream surrogate marker of upstream IL-1β activity ([@B29]). From a pharmacological perspective, drugs targeted against IL-1β and its receptors, initially used to treat non-vascular inflammatory conditions, are now being assayed as vasculoprotective and anti-atherothrombotic tools ([@B29]). In the present study, the stimulation of Ang-(1-7)/Mas axis revealed itself as an alternate strategy to minimize the impact of IL-1β on human VSMC pro-inflammatory activation. This is in line with other reports showing that in the context of neuroinflammation the pharmacological activation of the ACE2/Ang-(1-7) can reduce the inflammatory response of human retinal pigment epitelial cells to lipopolysaccharide ([@B36]). Furthermore, Ang-(1-7) may prevent the inflammation induced in astrocytes by physical stressors, such as radiation ([@B22]).

To further understand the mechanisms underlying the anti-inflammatory action of Ang-(1-7), the focus was set on common signaling pathways activated by both Ang II and IL-1β. The transcription factor NF-κB is a main redox-sensitive regulator of iNOS expression ([@B37]; [@B42]), and its over-activation by a wide array of stimuli has been associated to chronic inflammatory vascular diseases, such as atherosclerosis ([@B20]). Upstream of NF-κB, Ang-(1-7) promoted the inhibition of NADPH oxidase and diminished ROS generation, which in turn led to a marked attenuation of the NF-κB/iNOS axis and thus of human VSMC activation (**Figure [5](#F5){ref-type="fig"}**). This is in line with other reports showing that Ang-(1-7) negatively regulates NADPH oxidase activation elicited by Ang II in endothelial cells ([@B31]; [@B40]) or other non-vascular cell types, such as skeletal muscle or kidney tubular cells, among other ([@B13]; [@B23]). The activation of the IP3/Akt pathway, one of most relevant Mas-related signaling events acknowledged to date ([@B2]), might be on the basis of the protective effect of Ang-(1-7) against NOX-derived ROS formation and apoptosis in cerebral endothelial cells ([@B40]). In embryonic pancreatic explants, however, Ang-(1-7) rather seems to activate NADPH oxidase ([@B39]), which indicates that the precise mechanisms linking Mas activation and NADPH oxidase activity may be complex and still remain to be explored more in depth. Overall, our findings show that the inhibition of NADPH oxidase activity appears as a pivotal common intracellular target of Ang-(1-7) in protecting against inflammation triggered by stimuli of different nature. This mechanism might indeed be on the basis of the beneficial action of the heptapeptide on experimental atherosclerosis plaque formation ([@B41]). Whether Ang-(1-7) can modulate other ROS sources and total redox balance remains to be further explored.

![**Schematic diagram of the proposed action of the Ang-(1-7)/Mas axis on HAMSC pro-inflammatory signaling.** The binding of Ang II or IL-1β to their respective membrane receptors results in NADPH oxidase activation, which consecutively leads to NF-κB activation, iNOS induction and NO release. Through an effect mediated by Mas receptors, Ang-(1-7) promotes NADPH oxidase inhibition and thus attenuates the pro-inflammatory signaling triggered by Ang II, but also by other non-RAS inflammatory stimuli, such as IL-1β.](fphar-07-00482-g005){#F5}

Over the last years, pharmacological research has been undertaken to identify valuable tools to regulate the ACE2/Ang-(1-7)/Mas axis, with particular focus on Ang-(1-7) mimetics and ACE2 activity modulators ([@B10]; [@B35]). This study supports that activating or mimicking the ACE2/Ang-(1-7)/Mas axis may represent a valuable pharmacological opportunity to attenuate the pro-inflammatory environment that promotes and sustains the development of vascular diseases.
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